Results 41 to 50 of about 20,522 (204)
The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatins⃞
The combination of ezetimibe, an inhibitor of Niemann-Pick C1-like 1 protein (NPC1L1), and an HMG-CoA reductase inhibitor decreases cholesterol absorption and synthesis.
Dawn E. Telford +5 more
doaj +1 more source
ATP Citrate Lyase in Metabolic Disease: Mechanistic Insights and Clinical Potential
ATP citrate lyase (ACLY) is a central metabolic hub that diverts mitochondrial citrate to fuel de novo lipogenesis, cholesterol biosynthesis, and protein acetylation. Given its robust correlation with pathological changes in multiple human diseases, ACLY inhibitors featuring distinct pharmacological strengths have been developed for therapeutic ...
Wenbiao Wang +5 more
wiley +1 more source
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9[S]
Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks ...
Brandon Ason +18 more
doaj +1 more source
PTA alleviates atherosclerosis by regulating the MDM2/GPX4 axis‐mediated endothelial ferroptosis. ABSTRACT Endothelial ferroptosis is a crucial pathogenic driver of atherosclerosis (AS) progression. Protosappanin A (PTA), a bioactive compound from Caesalpinia sappan L., protects cardiovascular vessels by regulating ferroptosis.
Jiamei Fu +6 more
wiley +1 more source
Inhibitory effect of ezetimibe can be prevented by an administration interval of 4 h between alpha-tocopherol and ezetimibe [PDF]
Tocopherol is used not only as an ethical drug but also as a supplement. In 2008, it was reported that alpha-tocopherol is partly transported via an intestinal cholesterol transporter, Niemann-Pick C1-Like 1 (NPC1L1).
Shunsuke Nashimoto +7 more
core +1 more source
ABSTRACT Aims The triglyceride–glucose (TyG) index is associated with insulin resistance and cardiovascular disease (CVD), but the underlying mechanisms remain unclear. As ceramides are implicated in both insulin resistance and CVD, we investigated the association between the TyG index and plasma ceramides in individuals with Type 2 diabetes (T2D ...
Laure Carpentier +7 more
wiley +1 more source
Background The LDL-C lowering effect of ezetimibe has been attributed primarily to increased catabolism of LDL-C via up-regulation of LDL receptor (LDLR) and decreased cholesterol absorption.
Bin Xia +9 more
doaj +1 more source
The aim of this study was to develop multiparticulate systems with a combination of ezetimibe micellar systems and atorvastatin solid dispersions using croscarmellose as a hydrophilic vehicle and Kolliphor RH40 as a surfactant.
Carlos Torrado-Salmerón +5 more
doaj +1 more source
Ezetimibe Attenuates Atherosclerosis Associated with Lipid Reduction and Inflammation Inhibition. [PDF]
Ezetimibe, as a cholesterol absorption inhibitor, has been shown protecting against atherosclerosis when combined with statin. However, side by side comparison has not been made to evaluate the beneficial effects of ezetimibe alone versus statin. Herein,
Chunmiao Tie +6 more
doaj +1 more source
Novel ABCA1 mutations in Tangier disease associated with early‐onset type 2 diabetes: A case report
ABSTRACT Tangier disease (TD) is a rare disorder caused by mutations in the ATP‐binding cassette transporter A1 (ABCA1) gene with autosomal recessive inheritance and is characterized by extremely low high‐density lipoprotein cholesterol (HDL‐C) and premature atherosclerosis.
Makoto Wada +16 more
wiley +1 more source

